

Resource Summary Report

Generated by [dkNET](#) on Aug 27, 2026

pTwist-SARS-CoV-2 ?18 B.1.1.529

RRID:Addgene_179907

Type: Plasmid

Proper Citation

RRID:Addgene_179907

Plasmid Information

URL: <http://www.addgene.org/179907>

Proper Citation: RRID:Addgene_179907

Insert Name: SARS-CoV-2 B.1.1.529 Spike truncated to remove 18 amino acids

Organism: Severe acute respiratory syndrome coronavirus 2

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:34995482](#)

Vector Backbone Description: Backbone Marker:Twist; Backbone Size:6694; Vector Backbone:pTwist-CMV-BetaGlobin-WPRE-Neo; Vector Types:Mammalian Expression; Bacterial Resistance:Ampicillin

Comments: Balazs lab Clone 18

Plasmid Name: pTwist-SARS-CoV-2 ?18 B.1.1.529

Relevant Mutation: A67V; ?69-70; T95I; G142D; ?143-145; N211I; ?212; Ins214EPE; G339D; S371L; S373P; S375F; K417N; N440K; G446S; S477N; T478K; E484A; Q493R; G496S; Q498R; N501Y; Y505H; T547K; D614G; H655Y; N679K; P681H; N764K; D796Y; N856K; Q954H; N969K; L981F

Record Creation Time: 20220422T222032+0000

Record Last Update: 20260815T081125+0000

Ratings and Alerts

No rating or validation information has been found for pTwist-SARS-CoV-2 ?18 B.1.1.529.

No alerts have been found for pTwist-SARS-CoV-2 ?18 B.1.1.529.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 20 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Sulea T, et al. (2026) Multifunctional ACE2-nanobody fusion design for pan-specific neutralization and cardiovascular protection in SARS coronavirus infection. *Antimicrobial agents and chemotherapy*, 70(5), e0002426.

Finicle BT, et al. (2026) Endolysosomal trafficking regulator SH-BC-893 inhibits coronavirus entry in vitro and in vivo. *Scientific reports*, 16(1).

Ramasamy S, et al. (2025) Serological Assays Reveal No Evidence of Natural SARS-CoV-2 Infection in US Cattle. *Microorganisms*, 13(3).

Jung I, et al. (2025) Rapid Discovery of Potent Neutralizing Antibodies against SARS-CoV-2 through Directed Evolution of SARS-CoV-1 Antibodies. *Molecular pharmaceutics*, 22(9), 5316.

Chan CWF, et al. (2024) High-throughput screening of genetic and cellular drivers of syncytium formation induced by the spike protein of SARS-CoV-2. *Nature biomedical engineering*, 8(3), 291.

Connor RI, et al. (2024) Characteristics and Functions of Infection-enhancing Antibodies to the N-terminal Domain of SARS-CoV-2. *Pathogens & immunity*, 9(2), 1.

Antia A, et al. (2024) SARS-CoV-2 Omicron BA.1 Variant Infection of Human Colon Epithelial Cells. *Viruses*, 16(4).

Rocha VPC, et al. (2024) High-Content Imaging-Based Assay for SARS-CoV-2-Neutralizing Antibodies. *Vaccines*, 12(3).

Martins M, et al. (2024) The SARS-CoV-2 Spike is a virulence determinant and plays a major role on the attenuated phenotype of Omicron virus in a feline model of infection. *Journal of virology*, 98(3), e0190223.

Shukla N, et al. (2024) Pseudotyped virus infection of multiplexed ACE2 libraries reveals SARS-CoV-2 variant shifts in receptor usage. *PLoS pathogens*, 20(5), e1012044.

Costa Rocha VP, et al. (2024) A polyvalent RNA vaccine reduces the immune imprinting phenotype in mice and induces neutralizing antibodies against omicron SARS-CoV-2. *Heliyon*, 10(4), e25539.

Chawansuntati K, et al. (2024) Safety and immunogenicity of CoronaVac and ChAdOx1 heterologous prime-boost vaccines in an overweight population in Chiang Mai, Thailand. *Vaccine: X*, 18, 100475.

Shukla N, et al. (2024) Pseudotyped virus infection of multiplexed ACE2 libraries reveals SARS-CoV-2 variant shifts in receptor usage. *bioRxiv : the preprint server for biology*.

Fu JYL, et al. (2023) Humoral and T Cell Immune Responses against SARS-CoV-2 after Primary and Homologous or Heterologous Booster Vaccinations and Breakthrough Infection: A Longitudinal Cohort Study in Malaysia. *Viruses*, 15(4).

Wu CY, et al. (2023) The anti-SARS-CoV-2 effect and mechanism of Chiehyuan herbal oral protection solution. *Heliyon*, 9(7), e17701.

Connor RI, et al. (2023) Characteristics and functions of infection-enhancing antibodies to the N-terminal domain of SARS-CoV-2. *bioRxiv : the preprint server for biology*.

Khanna K, et al. (2022) Exploring antiviral and anti-inflammatory effects of thiol drugs in COVID-19. *American journal of physiology. Lung cellular and molecular physiology*, 323(3), L372.

Ho HPT, et al. (2022) Ganoderma microsporum immunomodulatory protein acts as a multifunctional broad-spectrum antiviral against SARS-CoV-2 by interfering virus binding to the host cells and spike-mediated cell fusion. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*, 155, 113766.

Shah M, et al. (2022) SARS-CoV-2 pan-variant inhibitory peptides deter S1-ACE2 interaction and neutralize delta and omicron pseudoviruses. *Computational and structural biotechnology journal*, 20, 2042.

Hung JN, et al. (2022) PEDOT:PSS in Solution Form Exhibits Strong Potential in Inhibiting SARS-CoV-2 Infection of the Host Cells by Targeting Viruses and Also the Host Cells. *Biomacromolecules*, 23(9), 3535.